Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Drugmaker AbbVie’s profit beats estimates on strong Humira sales

(Reuters) – U.S. drugmaker AbbVie Inc reported better-than-expected quarterly profit and revenue, driven by strong sales of its arthritis drug, Humira. Shares of the company, which also raised its full-year adjusted profit forecast, rose about 2 percent to $65.69 in premarket trading on Thursday. Sales of Humira jumped 18 percent to $3.11 billion in the […]

Read More »

Novartis posts first quarter profit despite dollar drag

(Reuters) – Swiss drugmaker Novartis (NOVN.VX) beat first-quarter profit forecasts on Thursday, defying the impact of a strong dollar thanks to surprisingly strong margins. The Basel-based group confirmed its guidance for sales and operating profit growth this year. Novartis has clinched a series of deals, including a $20 billion asset swap with GlaxoSmithKline (GSK.L) finalised […]

Read More »

Lilly profit beats estimates, helped by cost cuts

(Reuters) – Eli Lilly and Co (LLY.N) soundly beat quarterly profit estimates on lower-than-expected spending on research and marketing, but revenue slipped as the stronger dollar hurt sales outside the United States. The U.S. drugmaker hopes to begin rebounding this year from three years of plunging sales and earnings caused by patent expirations on some […]

Read More »

Lilly Reports First-Quarter 2015 Results

INDIANAPOLIS, April 23, 2015 /PRNewswire/ — Revenue declined 1 percent due to the unfavorable impact of foreign exchange rates and the continuing impact of Cymbalta and Evista patent expirations, largely offset by the inclusion of revenue from Novartis Animal Health, higher U.S. prices, and increased volume for several products. First-quarter 2015 earnings per share were […]

Read More »

Abbvie’s CEO Gonzalez: We’re Now In Pharma’s ‘Top Tier’

Abbvie chief executive Rick Gonzalez, whose team beat out several more established drug giants in the successful bid for cancer pill maker Pharmacyclics, said today new and existing products will bring “top tier growth through the rest of the decade and beyond.” Gonzalez’ bold statement, setting the stage for a larger Abbvie, came during this […]

Read More »

Roche more confident in beating Alzheimer’s after Biogen data

(Reuters) – Swiss drugmaker Roche has “renewed confidence” that drugs targeting potentially brain-destroying plaque can fight Alzheimer’s disease, following promising results with a product from a rival. Pharmaceuticals head Daniel O’Day said on Wednesday Roche would look again at prospects for two of its experimental Alzheimer’s drugs, both of which suffered setbacks in 2014, in […]

Read More »

Teva-Mylan-Perrigo: Merger Mania In Pursuit Of Generic Margins

There are very few assurances in life, but in the field of generic pharmaceuticals, there are three certainties we are about to witness: 1. This is now the Spring of offers and counter-offers with the prices for generic drug makers setting new highs. Yesterday the Teva (TEVA) $82 per share offer for Mylan MYL -0.04% […]

Read More »

Novo launches Saxenda in US, sees more launches in 2015

(Reuters) – Novo Nordisk has launched its Saxenda obesity drug in the United States, it said on Wednesday, a long-awaited milestone that will provide a new revenue stream for the Danish drugmaker. The company has said previously it expects sales from the drug to eventually reach $1 billion a year. It said in a statement […]

Read More »

Perrigo Rejects $30B Mylan Bid, Says Deal “Substantially Undervalues” Irish Firm

Pittsburgh, Penn.-based Mylan Inc. (MYL)’s $30 billion unsolicited bid for generic drugmaker Perrigo Company (PRGO) has been rejected by the company, after Perrigo said late Tuesday that the offer “substantially undervalues” Perrigo and “its future growth prospects and “is not in the best interests of Perrigo’s shareholders.” “Perrigo has a long history of driving above […]

Read More »

Biogen (BIIB) Loaded With Talented Women Execs, As CEO Pushes to Diversify Boardroom

Biogen has three women on its 10-member board of directors, an unusual feat in corporate America and the biotech industry. But instead of patting itself on the back with a round of attaboys and attagirls, the Cambridge powerhouse wanted to do more: help other companies put women on their boards. Where to find talented women? […]

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

August 2019 Focus: AI, AR/VR, Top 200 Medicines, Lions Health Takeaways, and more!


Ad Right Bottom